目的:抗原频率因地区和种族而异。因此,我们的目的是研究我们人群中血型抗原的患病率,并将印度各地血型抗原的患病率系统化.
方法:常规自愿O组献血者筛选21种血型抗原;C,C,E,e,K,k,Kpa,Kpb,Jka,Jkb,Fya,FYB,Lea,Leb,Lua,Lub,P1,M,N,S,s,使用市售单克隆抗血清通过柱凝集技术。进行了文献检索,以确定所有报告血型抗原患病率的研究,以估计这些抗原在该国的分区患病率。
结果:共纳入了符合所有纳入标准的9248个O组捐献者中的521名参与者。在研究小组中,男女比例为9:1,平均年龄为32.6岁(±10.01),范围为18-60岁.大多数供体446(85.6%)为D阳性。Rh中最常见的表型,刘易斯,凯尔,Duffy,基德,路德教会和跨国公司是CcDee(34.93%),乐(a-b+)(61.80%),K-k+(98.27%),Fy(a+b-)43.19%,Jk(a+b+)42.61%,Lu(a-b+)(99.61%),M+N+(48.17%),S-s+(45.29%)。与印度其他地区相比,南部地区的D和E抗原患病率明显较低。
结论:在印度南部和其他地区之间观察到血型抗原的患病率存在显着差异。血型表型的分区患病率对于及时管理同种免疫患者至关重要。
OBJECTIVE: The antigen frequencies vary across different regions and ethnic groups. Hence, we aimed to study the prevalence of blood group antigens in our population and to systemize the zone-wise prevalence of the same across India.
METHODS: Regular voluntary O group blood donors were screened for 21 blood group antigens; C, c, E, e, K, k, Kpa, Kpb, Jka, Jkb, Fya, Fyb, Lea, Leb, Lua, Lub, P1, M, N, S, s, using commercially available monoclonal antisera by column agglutination technology. A literature search was performed to identify all the studies that reported blood group antigens prevalence to estimate the zone-wise prevalence of these antigens in the country.
RESULTS: A total of 521 participants of 9248 O group donors meeting all the inclusion criteria were included. Among the study group, the male-to-female ratio was 9:1 with a mean age of 32.6 years (±10.01) ranging from 18-60 years. The majority of the donors 446 (85.6%) were D positive. The most common phenotypes among Rh, Lewis, Kell, Duffy, Kidd, Lutheran and MNSs were CcDee (34.93%), Le(a-b+) (61.80%), K-k+(98.27%), Fy(a+b-) 43.19%, Jk(a+b+) 42.61%, Lu(a-b+) ( 99.61%), M+N+ (48.17%), S-s+ (45.29%) respectively. The prevalence of D and E antigens was significantly lower in the South zone compared to other zones of India.
CONCLUSIONS: Significant difference in the prevalence of blood group antigens is observed between the South and other zones of India. Zone-wise prevalence of blood group phenotypes is essential in the timely management of alloimmunized patients.